Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1046 | Convalescent Immune Plasma Wiki | 1.00 |
| drug322 | Anticoagulation Agents (Edoxaban and/or high dose LMWH) Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate anticoagulation strategy = low-dose low-molecular weight heparin [LMWH], ambulatory no anticoagulation, i.e. placebo within this trial) in reduction of morbidity and mortality endpoints in patients with COVID-19.
Description: All-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism during follow-up (42 days). Thromboembolisms will be detected by duplex ultrasonography of arms and legs.
Measure: Combined endpoint: all-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism Time: 42 daysDescription: All-cause mortality during follow-up (42 days)
Measure: All-cause mortality Time: 42 daysDescription: Mortality related to venous thromboembolism during follow-up (42 days)
Measure: Mortality related to venous thromboembolism Time: 42 daysDescription: Mortality related to arterial thromboembolism during follow-up (42 days)
Measure: Mortality related to arterial thromboembolism Time: 42 daysDescription: Rate of venous and/ or arterial thromboembolism during follow-up (42 days) Thromboembolisms will be detected by duplex ultrasonography of arms and legs
Measure: Rate of venous and/ or arterial thromboembolism Time: 42 daysDescription: Rate and length of mechanical Ventilation during follow-up (42 days)
Measure: Rate and length of mechanical ventilation Time: 42 daysDescription: Length of initial stay at ICU after application of IMP during follow-up (42 days)
Measure: Length of initial stay at ICU after application of IMP Time: 42 daysDescription: Rehospitalisation during follow-up (42 days)
Measure: Rehospitalisation Time: 42 daysDescription: Rate and length of renal replacement therapy during follow-up (42 days)
Measure: Rate and length of renal replacement therapy Time: 42 daysDescription: Cardiac arrest/ CPR during follow-up (42 days)
Measure: Cardiac arrest/ CPR Time: 42 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports